Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

NKTR-102 for ovarian cancer patients, results from a subpopulation of patients from the Phase 2 clinical study of NKTR-102 in ovarian cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the data package required and the timing for regulatory approval of a new drug application (NDA) is very uncertain and difficult to predict due to broad regulatory discretion, changing standards of care, available approved therapies, the size of the completed clinical trials and the statistical significance of the results, the potential need for comparative clinical studies against approved therapies, and other important factors that are not within the control of Nektar; (iii) the results from the expanded Phase 2 clinical study for NKTR-102 in platinum-resistant/refractory ovarian cancer patients are unlikely to result in a review or an approval of an NDA by the United States Food and Drug Administration; (iv) the timing or success of the commencement or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to commercial and funding considerations, regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (v) the Phase 2 results for NKTR-102 in ovarian cancer patients previously treated with PLD set forth in this pre
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Nov. 16, 2010 eMix , a new business venture ... of its cloud-based image sharing technology for studies and ... expansion into the European marketplace, starting in Germany, Austria and Switzerland. ... features are: Automated report delivery – Enables a ...
... 2010 Berger & Montague, P.C. and ... for Lead Plaintiff and the Class in ... announced the following:IN THE UNITED STATES DISTRICT ... HEMISPHERX:BIOPHARMA, INC. LITIGATION:CIVIL ACTION NO.  09-CV-5262-PSD:SUMMARY NOTICE ...
Cached Medicine Technology:At RSNA, eMix to Exhibit EMR Delivery, Other New Features 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 3
(Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it ... Bali, Indonesia with their son, Isaac, said there was only one ... Mercy College in 2001 when Thompson was an undergraduate student and ... student at the time, was French and so she asked him. ... the United States when she was 7 years old. Nikel ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... News) -- Rising temperatures in the Atlantic Ocean may ... waters that are becoming warmer, an expansion that could ... A study of 40 species along the reefs ... the invasive and poisonous lionfish, according to researchers from ... University of North Carolina-Wilmington, who published their findings in ...
(Date:9/18/2014)... September 18, 2014 It’s been just a ... newest, patent pending bunion splint to website visitors, but already ... wrote: "I was absolutely delighted. It is perfect and I ... am wearing them. THANK YOU FOR LISTENING!!!" Another user ... saying, "The hole used to slip to the end of ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
... in sub-Saharan Africa do not necessarily lead to a higher ... Friday. ,Contradicting a "common belief" of such ... for Refugees (UNHCR) said that out of 12 refugee camps ... rate than surrounding host communities. ,The study, led ...
... 105-year-old exile who was detained for 30 years in his native ... citizen at a ceremony in Miami. ,Now, he ... ,And the former fisherman is convinced he will outlive the ... ,"He's far less healthy than I am, he can hardly ...
... lovers, otherwise allergic, beware. Cuddling your pet could prove ... found that a protein secreted from the cats skin could ... in people who have no specific allergy to the animals. ... suffer from allergy of one kind or another. ...
... of The American Journal of Medicine, researchers from the ... people 45 to 64 years of age who added ... cardiovascular disease (CVD) and reduce their death rate. ... at least 5 fruits and vegetables daily, exercising at ...
... - a molecule originally considered only a lowly messenger for ... where they are in the body and what they ... Medicine have discovered. ,The finding implies that ancient ... the human genome - a cell's genetic blueprint. It also ...
... autoimmune disease that mainly affects women in their reproductive ... improving quality of life. ,For men with ... However, no studies have been conducted to date on ... male SLE patients. In addition, the study identified intravenous ...
Cached Medicine News:Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 3Health News:Healthy Lifestyle can Reduce Cardiovascular Risk 2Health News:RNA Play a Vital Role in Gene Activity 2Health News:RNA Play a Vital Role in Gene Activity 3Health News:RNA Play a Vital Role in Gene Activity 4Health News:Infertility is Seen in Men With SLE 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: